Is vepotuzumab (POLIVY) on the market?

Vepotuzumab (POLIVY) was approved for use in the United States in June 2019 by the U.S. Food and Drug Administration (FDA) For medical use, was approved in Australia in October 2019, in the European Union in January 2020, in Canada in November 2020, and in January 2023 in China, it was approved by the National Medical Products Administration for domestic marketing.

VepotuzumabIndicated for the treatment of adults with relapsed or refractory diffuse large lymphomaB-cell lymphoma in combination with bendamustine and rituximab products,Vepotuzumab Anticombination rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adults with previously untreated diffuse large B-cell lymphoma (DLBCL). The most common side effects include neutropenia, thrombocytopenia and low levels of anemia, nerve damage (peripheral neuropathy), fatigue, diarrhea, fever, decreased appetite and pneumonia.

The domestic patent medicine Vepotolizumab has been on the market for a short time and has not yet entered the scope of medical insurance. It is an injectable preparation. The price of 30 mg per box may be around RMB 10,000. The price of the Hong Kong version of 140 mg per box may be around RMB 60,000 (the price may fluctuate due to exchange rates). It is listed overseas in Europe. The price of the version of vepotuzumab, specifications per box of 140 mg may be around 90,000 yuan (the price may fluctuate due to the exchange rate). The domestic original drug has basically the same ingredients as the foreign original drug and is expensive. There is currently no generic version of vepotuzumab on the market.